Adagio announces preclinical results for ventricular ablation catheter

Adagio Medical (ADGM) Holdings announced the publication of pre-clinical results of the Company’s next generation ultra-low temperature ablation, ULTA, technology designed to treat ventricular arrhythmias. The publication, which is titled “Initial Pre-Clinical Evaluation of the Augmented Ultra-Low Temperature Cryoablation Catheter for Ventricular Ablation” was published in the Journal of Cardiovascular Electrophysiology and describes significant functional improvements in ablation catheter performance compared to the Company’s first generation vCLAS ULTA catheter, including improved handling characteristics, better compatibility with standard laboratory practices and potential for 50-75% reduction in ablation time. The publication is authored by physicians from several leading ventricular ablation programs in Germany, Belgium and Canada